3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
46
Kidney Neoplasms
11
Carcinoma, Renal Cell
11
Urinary Bladder Neoplasms
9
Neoplastic Cells, Circulating
8
Neoplasms
8
Breast Neoplasms
7
Neoplasm Metastasis
5
Melanoma
5
Sarcoma
4
Carcinoma, Non-Small-Cell Lung
4
Testicular Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Disease
3
Colorectal Neoplasms
3
von Hippel-Lindau Disease
2
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Prostatic Hyperplasia
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Liver Neoplasms
2
Leukemia
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Clear-cell metastatic renal cell carcinoma
2
Interventions
Abiraterone Acetate
7
enzalutamide
6
olaparib
5
Prednisone
5
Pluvicto
5
Docetaxel
5
radium Ra 223 dichloride
4
darolutamide
4
cabazitaxel
3
Prednisolone
3
testosterone 17 beta-cypionate
2
fludarabine
2
abiraterone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
Genitourinary
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled